JPWO2020249873A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020249873A5 JPWO2020249873A5 JP2021574188A JP2021574188A JPWO2020249873A5 JP WO2020249873 A5 JPWO2020249873 A5 JP WO2020249873A5 JP 2021574188 A JP2021574188 A JP 2021574188A JP 2021574188 A JP2021574188 A JP 2021574188A JP WO2020249873 A5 JPWO2020249873 A5 JP WO2020249873A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- use according
- transgene
- adenoviral vector
- oncolytic adenoviral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962861339P | 2019-06-14 | 2019-06-14 | |
| US62/861,339 | 2019-06-14 | ||
| US202062988422P | 2020-03-12 | 2020-03-12 | |
| US62/988,422 | 2020-03-12 | ||
| PCT/FI2020/050422 WO2020249873A1 (en) | 2019-06-14 | 2020-06-12 | Oncolytic adenovirus and checkpoint inhibitor combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022536929A JP2022536929A (ja) | 2022-08-22 |
| JPWO2020249873A5 true JPWO2020249873A5 (ko) | 2023-06-20 |
Family
ID=71670283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021574188A Pending JP2022536929A (ja) | 2019-06-14 | 2020-06-12 | 腫瘍溶解性アデノウイルスとチェックポイント阻害剤の併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220251604A1 (ko) |
| EP (1) | EP3983004A1 (ko) |
| JP (1) | JP2022536929A (ko) |
| KR (1) | KR20220024495A (ko) |
| CN (1) | CN113924117A (ko) |
| AU (1) | AU2020292610A1 (ko) |
| BR (1) | BR112021025031A2 (ko) |
| CA (1) | CA3138834A1 (ko) |
| SG (1) | SG11202111820PA (ko) |
| WO (1) | WO2020249873A1 (ko) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022170919A1 (zh) * | 2021-02-09 | 2022-08-18 | 南京惟亚德生物医药有限公司 | 一种重组溶瘤腺病毒及其应用 |
| CN118055776A (zh) | 2021-10-04 | 2024-05-17 | 蒂尔坦生物制药有限公司 | 编码白细胞介素-7(il-7)多肽的溶瘤病毒载体 |
| WO2024180283A1 (en) * | 2023-03-01 | 2024-09-06 | Tilt Biotherapeutics Oy | Novel dosage regimen for an oncolytic adenoviral vector |
| WO2024207425A1 (en) * | 2023-04-07 | 2024-10-10 | Virogin Biotech (Shanghai) Ltd. | Combination of recombinant oncolytic virus and checkpoint inhibitor for the treatment of cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| CN117534755A (zh) | 2005-05-09 | 2024-02-09 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| CN105307671B (zh) | 2013-04-18 | 2020-09-04 | 蒂尔坦生物制药有限公司 | 增强过继细胞疗法 |
-
2020
- 2020-06-12 JP JP2021574188A patent/JP2022536929A/ja active Pending
- 2020-06-12 SG SG11202111820PA patent/SG11202111820PA/en unknown
- 2020-06-12 AU AU2020292610A patent/AU2020292610A1/en active Pending
- 2020-06-12 US US17/618,932 patent/US20220251604A1/en active Pending
- 2020-06-12 CA CA3138834A patent/CA3138834A1/en active Pending
- 2020-06-12 CN CN202080039001.0A patent/CN113924117A/zh active Pending
- 2020-06-12 WO PCT/FI2020/050422 patent/WO2020249873A1/en active Application Filing
- 2020-06-12 EP EP20742793.1A patent/EP3983004A1/en active Pending
- 2020-06-12 BR BR112021025031A patent/BR112021025031A2/pt unknown
- 2020-06-12 KR KR1020227000995A patent/KR20220024495A/ko unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Preclinical evaluation of chimeric antigen receptor–modified T cells specific to epithelial cell adhesion molecule for treating colorectal cancer | |
| Howells et al. | Oncolytic viruses—interaction of virus and tumor cells in the battle to eliminate cancer | |
| US11408005B2 (en) | Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells | |
| O'Bryan et al. | Oncolytic virotherapy for breast cancer treatment | |
| WO2021147121A1 (zh) | 修饰的免疫细胞及其应用 | |
| CA2640528C (en) | Oncolytic adenoviruses for cancer treatment | |
| Haviv et al. | Conditional gene targeting for cancer gene therapy | |
| BR122018004815A2 (pt) | adenovírus oncolítico que codifica proteína b7 | |
| JP7146739B2 (ja) | 癌を処置するためのアデノウイルスとチェックポイント阻害剤の組合せ | |
| WO2020037206A4 (en) | Recombinant myxoma viruses and uses thereof | |
| Joshi et al. | Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy | |
| US11485767B2 (en) | Multivalent PD-L1 binding compounds for treating cancer | |
| Wei et al. | Oncolytic Newcastle disease virus expressing chimeric antibody enhanced anti-tumor efficacy in orthotopic hepatoma-bearing mice | |
| Santos et al. | Modulation of the tumor microenvironment with an oncolytic adenovirus for effective T-cell therapy and checkpoint inhibition | |
| CA2487811A1 (en) | Use of adenoviruses replicating in a yb-1 dependent manner for the treatment of tumors | |
| JP2024510712A (ja) | Ｉｌ－１５をコードするアデノウイルス | |
| Pan et al. | α VEGFR2-MICA fusion antibodies enhance immunotherapy effect and synergize with PD-1 blockade | |
| Ekeke et al. | Fighting fire with fire: oncolytic virotherapy for thoracic malignancies | |
| Onimaru et al. | hTERT‐promoter‐dependent oncolytic adenovirus enhances the transduction and therapeutic efficacy of replication‐defective adenovirus vectors in pancreatic cancer cells | |
| JPWO2020249873A5 (ko) | ||
| Wang et al. | Novel combination oncolytic adenoviral gene therapy armed with Dm-dNK and CD40L for breast cancer | |
| Li et al. | Chimeric antigen receptor-immune cells against solid tumors: Structures, mechanisms, recent advances, and future developments | |
| WO2020258825A1 (zh) | 一套快速准确的三质粒溶瘤腺病毒重组包装系统Ad5MixPlus及其应用 | |
| Zou et al. | Gene therapy for hepatocellular carcinoma using adenoviral vectors delivering a gene encoding IL-17A-neutralizing antibody fragments | |
| JPWO2020037206A5 (ko) |